bit.bio

bit.bio designs and manufactures human cells to advance drug discovery and biomedical research enabling transformative treatments in human health. Using our proprietary deterministic cell programming technology, opti-ox, we convert induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. Our AI powered discovery platform identifies unique combinations of transcription factors that can program any desired cell type with exceptional purity and consistency at scale, with products ready to ship globally. To date, bit.bio’s ioCells portfolio features 45 products, including ioWild Type Cells, ioDisease Model Cells, and ioCRISPR-Ready Cells.